These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 37830733)

  • 1. Interactions between Metabolic Syndrome, MASLD, and Arterial Stiffening: A Single-Center Cross-Sectional Study.
    Solomon A; Negrea MO; Cipăian CR; Boicean A; Mihaila R; Rezi C; Cristinescu BA; Berghea-Neamtu CS; Popa ML; Teodoru M; Stoia O; Neamtu B
    Healthcare (Basel); 2023 Oct; 11(19):. PubMed ID: 37830733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic Involvement across the Metabolic Syndrome Spectrum: Non-Invasive Assessment and Risk Prediction Using Machine Learning.
    Solomon A; Cipăian CR; Negrea MO; Boicean A; Mihaila R; Beca C; Popa ML; Grama SM; Teodoru M; Neamtu B
    J Clin Med; 2023 Aug; 12(17):. PubMed ID: 37685725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vibration-Controlled Transient Elastography Scores to Predict Liver-Related Events in Steatotic Liver Disease.
    Lin H; Lee HW; Yip TC; Tsochatzis E; Petta S; Bugianesi E; Yoneda M; Zheng MH; Hagström H; Boursier J; Calleja JL; Goh GB; Chan WK; Gallego-Durán R; Sanyal AJ; de Lédinghen V; Newsome PN; Fan JG; Castéra L; Lai M; Harrison SA; Fournier-Poizat C; Wong GL; Pennisi G; Armandi A; Nakajima A; Liu WY; Shang Y; de Saint-Loup M; Llop E; Teh KK; Lara-Romero C; Asgharpour A; Mahgoub S; Chan MS; Canivet CM; Romero-Gomez M; Kim SU; Wong VW;
    JAMA; 2024 Apr; 331(15):1287-1297. PubMed ID: 38512249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Agile scores in MASLD and ALD: External validation and their utility in clinical algorithms.
    Papatheodoridi M; De Ledinghen V; Lupsor-Platon M; Bronte F; Boursier J; Elshaarawy O; Marra F; Thiele M; Markakis G; Payance A; Brodkin E; Castera L; Papatheodoridis G; Krag A; Arena U; Mueller S; Cales P; Calvaruso V; Delamarre A; Pinzani M; Tsochatzis EA
    J Hepatol; 2024 Oct; 81(4):590-599. PubMed ID: 38789011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Aortic Stiffness and Pressure Pulsatility With Noninvasive Estimates of Hepatic Steatosis and Fibrosis: The Framingham Heart Study.
    Cooper LL; Prescott BR; Xanthakis V; Benjamin EJ; Vasan RS; Hamburg NM; Long MT; Mitchell GF
    Arterioscler Thromb Vasc Biol; 2024 Jul; 44(7):1704-1715. PubMed ID: 38752348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence and Risk Factors of MASLD and Liver Fibrosis amongst the Penitentiary Population in Catalonia: The PRISONAFLD Study.
    Rivera-Esteban J; Jiménez-Masip A; Muñoz-Martínez S; Augustin S; Guerrero RA; Gabriel-Medina P; Ferrer-Costa R; Rodríguez-Frías F; Turu E; Marco A; Pericàs JM; On Behalf Of The Prisonafld Study Group Collaborators
    J Clin Med; 2023 Nov; 12(23):. PubMed ID: 38068330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Concurrent Metabolic Dysfunction-Associated Steatotic Liver Disease on Serial Non-invasive Fibrosis Markers in Chronic Hepatitis B.
    Con D; Tu S; Clayton-Chubb D; Lubel JS; Nicoll AJ; Sawhney R; Bloom S
    Dig Dis Sci; 2024 Apr; 69(4):1496-1506. PubMed ID: 38376788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing Liver Fibrosis in Type 2 Diabetes Mellitus Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease: The Role of Non-invasive Scoring Systems and Associated Factors.
    Naskar A; Mondal A; Chatterjee R; De RD; Roy S
    Cureus; 2024 Jun; 16(6):e62405. PubMed ID: 39011198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FibroMeter scores are predictive noninvasive markers of advanced and significant liver fibrosis in patients with chronic viral hepatitis or metabolic dysfunction-associated steatotic liver disease.
    Arvaniti P; Giannoulis G; Lygoura V; Gatselis NK; Gabeta S; Rigopoulou E; Koukoulis GK; Zachou K; Dalekos GN
    Ann Gastroenterol; 2023; 36(6):661-669. PubMed ID: 38023979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A combination of non-invasive tests for the detection of significant fibrosis in patients with metabolic dysfunction-associated steatotic liver disease is not superior to magnetic resonance elastography alone.
    Duman S; Kuru D; Gumussoy M; Kiremitci S; Gokcan H; Ulas B; Ellik Z; Ozercan M; Er RE; Karakaya F; Bodakci E; Erden A; Elhan AH; Savas B; Loomba R; Idilman R
    Eur Radiol; 2024 Jun; 34(6):3882-3888. PubMed ID: 37987833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in Transient Elastography with Glucagon-Like Peptide-1 Receptor Agonist Use in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Real-World Retrospective Analysis.
    Akhverdyan N; Wieland A; Sullivan S; Lindsay M; Swartwood S; Arndt G; Kaizer LK; Jensen T
    Metab Syndr Relat Disord; 2024 Oct; 22(8):608-618. PubMed ID: 38868900
    [No Abstract]   [Full Text] [Related]  

  • 12. Liver and atherosclerotic risks of patients with cryptogenic steatotic liver disease.
    Wang SW; Hsieh TH; Cheng YM; Wang CC; Kao JH
    Hepatol Int; 2024 Jun; 18(3):943-951. PubMed ID: 38227142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease.
    Younossi ZM; Paik JM; Stepanova M; Ong J; Alqahtani S; Henry L
    J Hepatol; 2024 May; 80(5):694-701. PubMed ID: 38286339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fatty Liver as Potential Biomarker of Atherosclerotic Damage in Familial Combined Hyperlipidemia.
    Mandraffino G; Morace C; Franzè MS; Nassisi V; Sinicropi D; Cinquegrani M; Saitta C; Scoglio R; Marino S; Belvedere A; Cairo V; Lo Gullo A; Scuruchi M; Raimondo G; Squadrito G
    Biomedicines; 2022 Jul; 10(8):. PubMed ID: 35892670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advanced fibrosis associates with atherosclerosis in subjects with nonalcoholic fatty liver disease.
    Chen Y; Xu M; Wang T; Sun J; Sun W; Xu B; Huang X; Xu Y; Lu J; Li X; Wang W; Bi Y; Ning G
    Atherosclerosis; 2015 Jul; 241(1):145-50. PubMed ID: 25988358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FibroScan-aspartate transaminase: A superior non-invasive model for diagnosing high-risk metabolic dysfunction-associated steatohepatitis.
    Yin JY; Yang TY; Yang BQ; Hou CX; Li JN; Li Y; Wang Q
    World J Gastroenterol; 2024 May; 30(18):2440-2453. PubMed ID: 38764767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gender Differences in Liver Steatosis and Fibrosis in Overweight and Obese Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease before and after 8 Weeks of Very Low-Calorie Ketogenic Diet.
    Rinaldi R; De Nucci S; Donghia R; Donvito R; Cerabino N; Di Chito M; Penza A; Mongelli FP; Shahini E; Zappimbulso M; Pesole PL; Coletta S; Triggiani V; Cozzolongo R; Giannelli G; De Pergola G
    Nutrients; 2024 May; 16(10):. PubMed ID: 38794646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prevalence of nonalcoholic fatty liver disease in Chinese adults screened by vibration controlled transient elastography and its diagnostic discrepancy compared with ultrasound.
    Ding Y; Jiang L; Wang Q; Zhao W; Zhou X; Lu J; Tian T; Yu C; Xu X; Guo W; Zhang Q; Song C
    Clin Res Hepatol Gastroenterol; 2022 Oct; 46(8):101951. PubMed ID: 35605893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring the landscape of steatotic liver disease in the general US population.
    Ciardullo S; Carbone M; Invernizzi P; Perseghin G
    Liver Int; 2023 Nov; 43(11):2425-2433. PubMed ID: 37592856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prevalence and predictors of metabolic dysfunction-associated steatotic liver disease and fibrosis/cirrhosis among adolescents/young adults.
    Perumpail BJ; Manikat R; Wijarnpreecha K; Cholankeril G; Ahmed A; Kim D
    J Pediatr Gastroenterol Nutr; 2024 Jul; 79(1):110-118. PubMed ID: 38623942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.